Palatin Technologies (PTN)

$0.09 -0.08 (-44.65%)
Market Cap 2.45M
Revenue (ttm) 4.49M
Net Income (ttm) -29.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -662.36%
Debt to Equity Ratio 0.00
Volume 14,571,800
Avg Vol 3,131,146
Day's Range N/A - N/A
Shares Out 26.01M
Stochastic %K 5%
Beta 0.94
Analysts Strong Sell
Price Target $7.00

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 495 2200
Fax: 609 495 2202
Website: palatin.com
Address:
Cedar Brook Corporate Center, 4-B Cedar Brook Drive, Cranbury, United States
Stocks787
Stocks787 Nov. 14 at 5:18 PM
$PTN 1.00
0 · Reply
GetOverHere_
GetOverHere_ Nov. 14 at 8:31 AM
$AMTM $SCCO $PTN $GSAT ,
0 · Reply
GetOverHere_
GetOverHere_ Nov. 14 at 8:18 AM
$EL $RCL $PTN $HMC ,
0 · Reply
JOHNB21400
JOHNB21400 Nov. 13 at 9:04 PM
$PTN
0 · Reply
Rollercoaster22
Rollercoaster22 Nov. 13 at 3:32 PM
$PTN Dream on. Won't happen.
1 · Reply
jamestocklover
jamestocklover Nov. 13 at 3:30 PM
$WXM HITACHI DISTRIBUTORSHIP DEAL. OVERSOLD ZONE. IT IS ABOUT TO EXPLODE. PURE ACCUMULATION FOR $1 - $2 RANGE🔥🚀💯 $NVVE 👀 $TNMG 👀 $IDN 👀 $PTN 👀
0 · Reply
m0vingPawn01
m0vingPawn01 Nov. 13 at 3:02 PM
$PTN can’t move without volume.. and nobody buying this stock
0 · Reply
topstockalerts
topstockalerts Nov. 13 at 1:33 PM
$PTN keep it on your radar..
0 · Reply
Bullish_Scanner
Bullish_Scanner Nov. 13 at 1:21 PM
Premarket Gappers $MRSN $NVVE $TNMG $SOND $PTN
0 · Reply
kikmontero
kikmontero Nov. 13 at 1:08 PM
$PTN What happen with Vyseeli royalties? What happen with male DS program? These guys are going to clean your account next year if you trust in their smoke dreams. Short it
0 · Reply
Latest News on PTN
Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript

Nov 13, 2025, 3:41 PM EST - 2 days ago

Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:30 AM EST - 2 days ago

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Nov 12, 2025, 12:15 PM EST - 3 days ago

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Nov 6, 2025, 8:00 AM EST - 9 days ago

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

Nov 6, 2025, 7:30 AM EST - 9 days ago

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

Sep 22, 2025, 7:30 AM EDT - 7 weeks ago

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Aug 18, 2025, 8:05 AM EDT - 3 months ago

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Palatin Announces 1-for-50 Reverse Stock Split

Aug 8, 2025, 4:00 PM EDT - 3 months ago

Palatin Announces 1-for-50 Reverse Stock Split

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

Jul 15, 2025, 7:30 AM EDT - 4 months ago

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript

May 15, 2025, 6:43 PM EDT - 6 months ago

Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

May 14, 2025, 7:30 AM EDT - 6 months ago

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

May 9, 2025, 7:30 AM EDT - 6 months ago

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

Palatin Technologies Announces Closing of Reduced Public Offering

May 8, 2025, 10:19 PM EDT - 6 months ago

Palatin Technologies Announces Closing of Reduced Public Offering

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 7, 2025, 8:26 PM EDT - 6 months ago

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

May 7, 2025, 5:20 PM EDT - 6 months ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025, 8:15 AM EDT - 6 months ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 7, 2025, 8:00 AM EDT - 6 months ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

May 5, 2025, 7:30 AM EDT - 6 months ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 29, 2025, 7:30 AM EDT - 7 months ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 17, 2025, 7:30 AM EDT - 7 months ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Appeals NYSE American Notice of Delisting

Apr 14, 2025, 7:00 AM EDT - 7 months ago

Palatin Appeals NYSE American Notice of Delisting

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 4:01 PM EDT - 7 months ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Apr 10, 2025, 7:30 AM EDT - 7 months ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 31, 2025, 7:30 AM EDT - 8 months ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 28, 2025, 7:30 AM EDT - 8 months ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Mar 25, 2025, 7:30 AM EDT - 8 months ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Feb 15, 2025, 5:41 AM EST - 9 months ago

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 13, 2025, 7:30 AM EST - 9 months ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 10, 2025, 4:00 PM EST - 9 months ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 7, 2025, 8:00 AM EST - 10 months ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Feb 6, 2025, 7:30 AM EST - 10 months ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Jan 28, 2025, 7:30 AM EST - 10 months ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 19, 2024, 7:30 AM EST - 11 months ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Dec 16, 2024, 7:30 AM EST - 11 months ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Nov 25, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Nov 14, 2024, 12:49 PM EST - 1 year ago

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 14, 2024, 7:30 AM EST - 1 year ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 8, 2024, 9:57 AM EST - 1 year ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Nov 4, 2024, 7:30 AM EST - 1 year ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 7, 2024, 4:15 PM EDT - 1 year ago

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Oct 1, 2024, 2:55 PM EDT - 1 year ago

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 28, 2024, 7:30 AM EDT - 1 year ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Aug 22, 2024, 7:30 AM EDT - 1 year ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Stocks787
Stocks787 Nov. 14 at 5:18 PM
$PTN 1.00
0 · Reply
GetOverHere_
GetOverHere_ Nov. 14 at 8:31 AM
$AMTM $SCCO $PTN $GSAT ,
0 · Reply
GetOverHere_
GetOverHere_ Nov. 14 at 8:18 AM
$EL $RCL $PTN $HMC ,
0 · Reply
JOHNB21400
JOHNB21400 Nov. 13 at 9:04 PM
$PTN
0 · Reply
Rollercoaster22
Rollercoaster22 Nov. 13 at 3:32 PM
$PTN Dream on. Won't happen.
1 · Reply
jamestocklover
jamestocklover Nov. 13 at 3:30 PM
$WXM HITACHI DISTRIBUTORSHIP DEAL. OVERSOLD ZONE. IT IS ABOUT TO EXPLODE. PURE ACCUMULATION FOR $1 - $2 RANGE🔥🚀💯 $NVVE 👀 $TNMG 👀 $IDN 👀 $PTN 👀
0 · Reply
m0vingPawn01
m0vingPawn01 Nov. 13 at 3:02 PM
$PTN can’t move without volume.. and nobody buying this stock
0 · Reply
topstockalerts
topstockalerts Nov. 13 at 1:33 PM
$PTN keep it on your radar..
0 · Reply
Bullish_Scanner
Bullish_Scanner Nov. 13 at 1:21 PM
Premarket Gappers $MRSN $NVVE $TNMG $SOND $PTN
0 · Reply
kikmontero
kikmontero Nov. 13 at 1:08 PM
$PTN What happen with Vyseeli royalties? What happen with male DS program? These guys are going to clean your account next year if you trust in their smoke dreams. Short it
0 · Reply
WallStWireAds
WallStWireAds Nov. 13 at 12:32 PM
$PTN https://caplynx.io/5xOxQS9
0 · Reply
Stocks787
Stocks787 Nov. 13 at 10:39 AM
$PTN $1.00
0 · Reply
kikmontero
kikmontero Nov. 13 at 6:34 AM
$PTN Spana is ready to steal your money again 💰💲
0 · Reply
Slitherin
Slitherin Nov. 12 at 9:29 PM
HOUR stock will be the next 5X Penny play $NVVE $PTN $KIDZ $FLY $PLBY worth watching for pre market
0 · Reply
m0vingPawn01
m0vingPawn01 Nov. 12 at 9:19 PM
$PTN yeah, this ain’t it. Why did it halt twice today and then tank after hours
0 · Reply
GabriellaTanner
GabriellaTanner Nov. 12 at 8:52 PM
$PTN NXXT breaks 1.97 and 2.00 becomes a magnet 🧲
0 · Reply
m0vingPawn01
m0vingPawn01 Nov. 12 at 8:17 PM
$PTN I mean no.. no volume.. what you expect? This stock seems to be a dud for a year straight
0 · Reply
Dark_Angle
Dark_Angle Nov. 12 at 8:04 PM
$AITX $PTN $CARM I heard a great riddle yesterday…. So… It is stronger then God, more eviler then the Devil… Poor people have it… The rich need it, and if you eat it you will die… what am I?
3 · Reply
barkNdunbite
barkNdunbite Nov. 12 at 8:00 PM
$PTN come on get some lubricant
0 · Reply
HellenJune
HellenJune Nov. 12 at 6:30 PM
$PTN Someone here, please put a spell on these scammers, to cause them some instant chilli burrito effect
0 · Reply
m0vingPawn01
m0vingPawn01 Nov. 12 at 6:13 PM
$PTN 25% swings in an hour insane. Only big boys making money
0 · Reply
HellenJune
HellenJune Nov. 12 at 6:09 PM
$PTN placed an order to 8.9 and got it with 17... so got really fried today... and this price fluctuates as a the biggest scam ever
0 · Reply